Discover how a groundbreaking peroxisome-related gene signature not only forecasts clinical outcomes but also unveils its significant association with the immune microenvironment in low-grade glioma, offering new avenues for personalized treatment strategies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao et al., PeerJ 2024
<!– DOI: 10.7717/peerj.16874 //–>
https://doi.org/10.7717/peerj.16874
This study introduces a novel prognostic model for low-grade glioma (LGG) patients, focusing on the role of peroxisome-related genes (PRGs). Utilizing data from The Cancer Genome Atlas (TCGA), researchers identified two distinct LGG subtypes based on PRG expression. A 14-gene signature was developed through rigorous statistical analysis, which was found to be a strong independent predictor of overall survival (OS) in LGG patients. This signature’s predictive accuracy was confirmed using an external dataset (GSE107850) from the Gene Expression Omnibus (GEO). Additionally, a nomogram incorporating the gene signature and patient age demonstrated enhanced prognostic capability. Biological pathway analyses linked the high-risk group to neuroactive ligand-receptor interaction and phagosome pathways, alongside a reduced immune status. Experimental validation showed that inhibiting two genes from the signature, ATAD1 and ACBD5, significantly reduced proliferation and induced apoptosis in glioma cell lines. This research not only provides a valuable tool for personalized OS prediction in LGG but also highlights the potential therapeutic targets within the peroxisome-related pathways.